NAD+ and Age-Related Macular Degeneration: How Far Does the Evidence Go?

Written by the Nuvirox Research Team

Short answer: the retinal biology is well established, but the human clinical evidence is still mostly one step removed from AMD itself. Researchers have clearly documented that retinal NAD+ falls with age and falls further in age-related macular degeneration. Human randomized trials of a related NAD+ precursor, niacin, have shown benefits in glaucoma. But for AMD specifically, the strongest NAD+ precursor data — for nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — still comes from mouse models, not people.

Why does the retina care about NAD+ so much?

The retina is one of the most metabolically demanding tissues in the body, constantly using energy to process light and maintain photoreceptor cells. NAD+ is essential for that energy production, for antioxidant defense against light-driven oxidative stress, and for the activity of enzymes like sirtuins and PARPs that help retinal cells cope with damage. As NAD+ declines with age — in the retina as elsewhere — this metabolic and antioxidant capacity is thought to weaken, which researchers believe contributes to the oxidative stress and inflammation seen in AMD.

What is the difference between the niacin evidence and the NAD+ precursor evidence?

A 2024 narrative review in the journal Nutrients laid out the state of the science for both glaucoma and AMD. For glaucoma, randomized controlled trials of niacin supplementation showed measurable, dose-dependent improvements in visual field sensitivity and inner retinal function in human patients. That is real human RCT evidence — but it is for glaucoma, a different retinal disease, and for niacin, which is chemically distinct from NR and NMN even though all three feed into NAD+ production.

For AMD specifically, the review describes the evidence as more preliminary: nicotinamide supplementation may improve rod cell function and protect against oxidative stress-induced damage, and population studies show people with AMD tend to have lower dietary niacin intake. But this is associative and mechanistic, not a completed randomized human AMD trial for NR or NMN.

What human studies actually show

Human RCT evidence exists, but for a related disease. Randomized controlled trials of niacin in glaucoma patients found significant, dose-dependent improvements in visual field sensitivity and inner retinal function. This tells us NAD+ precursors can measurably affect human retinal function in a related oxidative-stress-driven eye disease — a reasonable basis for interest, but not proof of an AMD-specific effect.

Mouse models directly support an AMD-relevant protective effect. A study using three separate mouse models of retinal degeneration, including light-induced retinal degeneration and two models of retinitis pigmentosa, found that systemic nicotinamide riboside treatment was protective against retinal damage across all three models. Separately, nicotinamide mononucleotide reduced cellular senescence and inflammation in retinal pigment epithelial cells exposed to an oxidant used to model dry AMD.

The honest gap: no completed human randomized trial has tested NR or NMN specifically in people with AMD. The population and cross-sectional data (lower dietary niacin intake associated with AMD) are suggestive but cannot establish that supplementation changes disease progression, and eye disease trials generally take years to produce meaningful endpoints like preserved visual acuity.

What NAD+ supplementation won’t do for macular degeneration

AMD is diagnosed and staged by an ophthalmologist through dilated eye exams and imaging, and current standard treatments (including AREDS2-formula supplements, anti-VEGF injections for wet AMD, and monitoring for dry AMD) are backed by dedicated, disease-specific trials that NAD+ precursors have not yet gone through. A general NAD+ supplement is not a substitute for AREDS2-type formulations or for regular ophthalmology follow-up, and this article isn’t asking you to treat it that way.

If you notice blurred or distorted central vision, straight lines appearing wavy, or a blind spot developing, see an ophthalmologist promptly — early intervention affects outcomes in AMD, and no supplement changes that timeline.

Dosing context from the closest available human data

The glaucoma RCTs showing visual field improvements used niacin, generally in the range of 1.5 to 3 grams per day under medical supervision — a very different dose and compound from the 500 mg of nicotinamide riboside used in typical over-the-counter NAD+ supplements, and not one we would suggest attempting to replicate without medical guidance given niacin's dose-dependent side effects at that scale. For general NAD+ support, NR trials in other populations have used 250 mg to 2,000 mg per day.

Frequently asked questions

Can NAD+ supplements prevent or reverse macular degeneration?

There’s no human trial evidence for that yet. Mouse studies show a protective effect on retinal degeneration, and a related eye disease (glaucoma) has human RCT support for niacin, but AMD-specific human data for NR or NMN doesn’t exist.

Is niacin the same as the NAD+ precursor in NAD+ Restore?

No. Niacin (nicotinic acid) is a different B3 form from nicotinamide riboside, and the glaucoma trials used gram-scale niacin doses under medical supervision, not the 500 mg NR dose used in typical supplements.

Should I stop taking AREDS2 supplements in favor of an NAD+ supplement?

No. AREDS2-formula supplements have disease-specific trial evidence for slowing AMD progression. NAD+ precursors have not been tested against or alongside AREDS2 in AMD patients, so this isn’t a substitution to make.

What eye symptoms should prompt a doctor visit rather than a supplement?

Blurred or distorted central vision, wavy straight lines, or a new blind spot warrant a prompt ophthalmology visit, since early treatment affects AMD outcomes.

The bottom line

Retinal NAD+ decline is a documented part of AMD biology, and a related eye disease has genuine human trial support for a NAD+ precursor. But for AMD itself, the NR and NMN evidence is still preclinical. That is worth watching, not worth treating as settled.

References

1. Gemae MR, Bassi MD, Wang P, Chin EK, Almeida DRP. NAD+ and Niacin Supplementation as Possible Treatments for Glaucoma and Age-Related Macular Degeneration: A Narrative Review. Nutrients. 2024;16(16):2795. doi:10.3390/nu16162795.
2. Systemic Treatment with Nicotinamide Riboside is Protective in Three Mouse Models of Retinal Degeneration. bioRxiv. 2019.
3. Ren C, Hu C, Wu Y, et al. Nicotinamide Mononucleotide Ameliorates Cellular Senescence and Inflammation Caused by Sodium Iodate in RPE. 2022. doi:10.1155/2022/5961123.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.